Drug Trial Radar · NCT00724984
Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma
Last checked: Nov 19, 2026Latest source record: Apr 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Jul 2008
Primary completion
Nov 2012
Sponsor
- Lead sponsor
- Pharmacyclics LLC.AbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jul 30, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The first part of the study will determine the highest dose of study drug that can be taken without causing serious side effects in patients with lymphoma. The appropriate dose determined from the first part of the study will be used in the second part of the study to assess disease response in 2 different types of lymphoma patients.
Conditions
- Lymphoma
- Hodgkin Disease
- Lymphoma, Non-Hodgkin
Interventions
PCI-24781Drug
Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart ("BID"), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I (Dose Escalation Phase): MTD and DLTs of PCI-24781 Administered Twice Daily (BID) Measure: Disease ResponseTime frame: From the Date of PCI-24781 first administration to Cycle 2 Day 1
- Phase II: Overall Response Rate (CR+PR)Time frame: From first response assessment (day 22 to 28 of Cycle 2) to last response assessment on day 22-28 in even-numbered cycles
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California
Northwestern University Medical School
Chicago, Illinois
Horizon Oncology Center
Lafayette, Indiana
University of Massachusetts Medical School
Worcester, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Nebraska Methodist Hospital
Omaha, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska
University of Vermont and Fletcher Allen Health Care
Burlington, Vermont
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.